Business Context and Reporting Period
Company: Mustang Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 7, 2022
Reporting Period: Event date December 7, 2022
The filing reports the entry into a material definitive agreement regarding an existing loan facility. Mustang Bio, Inc. is a Delaware corporation with its principal executive offices in Worcester, Massachusetts, and its common stock trades on the NASDAQ Capital Market under the symbol "MBIO".
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or margin data. The only financial metric disclosed relates to the principal amount of an existing loan agreement:
- Loan Principal: $75.0 million (Original Loan Agreement dated March 4, 2022).
- Lender: Runway Growth Finance Corp.
The filing text does not provide a clear value for current debt balances, liquidity positions, or other financial metrics as of the reporting date.
Material Changes
The material change reported is the execution of the First Amendment to the $75.0 million Loan and Security Agreement with Runway Growth Finance Corp. The amendment specifically:
- Replaced LIBOR-based benchmark rates applicable to outstanding loans with SOFR-based rates.
- Included adjustments as specified in the First Amendment.
- Amended certain definitions and other provisions of the original agreement.
Guidance, Outlook, and Risks
Management Commentary: The filing contains no forward-looking guidance, outlook, or management commentary beyond the description of the amendment.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies. The amendment addresses the transition from LIBOR to SOFR, which is a standard market adjustment to ensure the loan agreement remains compliant with evolving benchmark standards.
Unusual Items: No unusual items were reported in this filing.
Key Facts for Investor Verification
- Verify the specific SOFR adjustment terms and spread details in the full text of the First Amendment (Exhibit 10.1).
- Confirm the current outstanding principal balance of the $75.0 million loan facility, as this filing only references the original agreement amount.
- Review subsequent filings for any impact of the interest rate benchmark change on the company's future interest expense.